Reference : Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepa...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Systems Biomedicine
http://hdl.handle.net/10993/45952
Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection.
English
Kraemer, Marcel [> >]
Krawczyk, Marcin [> >]
Noor, Fozia mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) >]
Grunhage, Frank [> >]
Lammert, Frank [> >]
Schneider, Jochen mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) >]
2019
Journal of clinical medicine
8
1
Yes (verified by ORBilu)
2077-0383
Switzerland
[en] Fibroscan ; HCV ; SSAO activity ; VAP-1 ; chronic liver diseases ; fibrosis ; liver stiffness ; semicarbazide-sensitive amino oxidase ; vascular adhesion protein 1
[en] Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increases oxidative stress. In chronic liver diseases, it plays a role in leukocyte infiltration and fibrogenesis. Here, we measured VAP-1 plasma concentration and its SSAO activity in 322 patients with chronic hepatitis C infection and evaluated the association of VAP-1 with fibrosis stages. VAP-1 concentration strongly correlated with liver stiffness and was the second strongest influencing variable after gamma-glutamytransferase (GGT) for liver stiffness in regression analysis. The VAP-1 concentration increased with advancing fibrosis stages and the highest concentrations were found in patients with cirrhosis. According to the receiver operating characteristic (ROC) analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity 74%; specificity 72%). SSAO activity correlated only moderately with liver stiffness, showing a relatively small increase in advanced fibrosis. To our knowledge, this is the first study on VAP-1 in chronic hepatitis C infection showing its association with progressive fibrosis. In conclusion, VAP-1 plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for monitoring fibrogenesis in patients with chronic hepatitis C infection.
http://hdl.handle.net/10993/45952
10.3390/jcm8010103

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Kraemer et al 2019.pdfPublisher postprint1.01 MBView/Open

Additional material(s):

File Commentary Size Access
Open access
Supplementary file_final_JCM-404601.docx121.18 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.